表紙
市場調查報告書

大腸癌 (CRC) :流行病學預測

Colorectal Cancer: Epidemiology Forecast to 2028

出版商 GlobalData 商品編碼 918520
出版日期 內容資訊 英文 47 Pages
訂單完成後即時交付
價格
Back to Top
大腸癌 (CRC) :流行病學預測 Colorectal Cancer: Epidemiology Forecast to 2028
出版日期: 2019年11月30日內容資訊: 英文 47 Pages
簡介

主要8個國家 (美國,法國,德國,義大利,西班牙,英國,日本,中國) 大腸癌 (CRC) 和確診的發病數量,預測將從2018年的82萬7,242件,增加到2028年的107萬8,959件,以AGR (年度成長率) 3.04%的速度成長。

本報告提供全球主要9個國家的大腸癌 (CRC) 市場相關調查分析,提供最新的流行病學預測相關的系統性資訊。

第1章 目錄

第2章 摘要整理

第3章 流行病學

  • 疾病的背景
  • 危險因素和合併症
  • 全球趨勢·過去趨勢
  • 預測手法
  • 大腸癌 (CRC)的流行病學預測
  • 議論

第4章 附錄

目錄
Product Code: GDHCER220-19

Colorectal cancer (CRC) is a cancer that occurs in the large intestine or large bowel (Centers for Disease Control and Prevention, 2019). Most CRCs start as abnormal growths known as polyps on the inner lining of the colon or rectum. Over time, some polyps may turn into cancer (American Cancer Society, 2018). Common symptoms of CRC are: blood in stool, stomach pain, aches or cramps that do not go away, weight loss, and a persistent change in bowel habit. CRC screening tests help to find colorectal cancer at an early stage and/or remove pre-cancerous polyps in the colon or rectum (American Cancer Society, 2018).

GlobalData epidemiologists utilized country-specific cancer registries, national databases, and robust peer-reviewed journal articles to build the forecast for the diagnosed incident cases and diagnosed prevalent cases of CRC in the 8MM.

The following data describes epidemiology of CRC. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of CRC in the 8MM, from 827,242 cases in 2018 to 1,078,959 cases in 2028 at an AGR of 3.04% during the forecast period. The diagnosed prevalent cases of CRC in the 8MM are also expected to increase, from 5,307,305 cases in 2018 to 7,303,381 cases in 2028, at an AGR of 3.76% over the forecast period. CRC is more common in men than women and the risk of developing CRC increases with age. These trends are reflected in GlobalData's forecast for the diagnosed incident cases, with older age groups (ages ≥65 years) contributing the highest proportion of the incident cases in the 8MM.

Scope

  • The Colorectal Cancer (CRC) Epidemiology Report and Model provide an overview of the risk factors and global trends of CRC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiological forecast for the diagnosed incident cases of CRC segmented by sex, and age (ages ≥18 years) in these markets. - The diagnosed incident cases of CRC are further segmented by stage at diagnosis (stage I, II, III, and IV), by type of molecular markers (KRAS, NRAS, MET amplification, MSI-dMMR, HER2 amplification, NTRK gene fusion, and BRAF V600E), and sidedness (right-sided and left-sided). The report also includes diagnosed incident cases of CRC by population with curable synchronous liver metastases, five-year diagnosed prevalent cases of CRC, and all-time diagnosed prevalent cases of CRC.
  • The colorectal cancer epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.
  • The Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Reasons to buy

The Colorectal Cancer Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global colorectal cancer market.
  • Quantify patient populations in the global colorectal cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for colorectal cancer therapeutics in each of the markets covered.
  • Understand magnitude of colorectal cancer population by stage at diagnosis.

Table of Contents

1. Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Colorectal Cancer: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Sources Not Used
    • 3.4.3 Forecast Assumptions and Methods
  • 3.5 Epidemiological Forecast for CRC (2018-2028)
    • 3.5.1 Diagnosed Incident Cases of CRC
    • 3.5.2 Age-Specific Diagnosed Incident Cases of CRC
    • 3.5.3 Sex-Specific Diagnosed Incident Cases of CRC
    • 3.5.4 Diagnosed Incident Cases of CRC by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of CRC by Molecular Markers
    • 3.5.6 Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis
    • 3.5.7 Diagnosed Incident Cases of CRC by Sidedness
    • 3.5.8 Five-Year Diagnosed Prevalent Cases of CRC
    • 3.5.9 All-Time Diagnosed Prevalent Cases of CRC
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Limitations of Analysis
    • 3.6.3 Strengths of Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

  • Table 1: Risk Factors and Comorbid Conditions Associated with CRC
  • Table 2: 8MM, Diagnosed Incident Cases of CRC by Molecular Markers, N, Both Sexes, Ages ≥18 Years, 2018
  • Table 3: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2019

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018 and 2028
  • Figure 2: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018 and 2028
  • Figure 3: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Men, Ages ≥18 Years, 2018-2028
  • Figure 4: 8MM, Diagnosed Incidence of CRC (Cases per 100,000 Population), Women, Ages ≥18 Years, 2018-2028
  • Figure 5: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC
  • Figure 6: 8MM, Sources Used to Forecast the Five-Year Diagnosed and Diagnosed Prevalent Cases of CRC
  • Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of CRC by Stage at Diagnosis
  • Figure 8: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Molecular Markers
  • Figure 9: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastases
  • Figure 10: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of CRC by Sidedness
  • Figure 11: 8MM, Diagnosed Incident Cases of CRC, N, Both Sexes, ≥18 Years, 2018
  • Figure 12: 8MM, Age-Specific Diagnosed Incident Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 13: 8MM, Sex-Specific Diagnosed Incident Cases of CRC, N, Ages ≥18 Years, 2018
  • Figure 14: 8MM, Diagnosed Incident Cases of CRC by Stage at Diagnosis, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 15: 8MM, Diagnosed Incident Cases of CRC by Population with Curable Synchronous Liver Metastasis, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 16: 8MM, Diagnosed Incident Cases of CRC by Sidedness, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 17: 8MM, Five-Year Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
  • Figure 18: 8MM, Diagnosed Prevalent Cases of CRC, N, Both Sexes, Ages ≥18 Years, 2018
Back to Top